Haematologica Reports 2005; 1(issue 11): 2-6[prev][index][next]
Thalidomide alone or in combination: results in
refractory patients
Jesús F. San Miguel, Servicio de Hematologia, Hospital Clinico
Universitario de Salamanca, Paseo de San Vicente 58-182, 37007
Salamanca, Spain
Direct phone: +34.923.291384
Main phone: +34.923.291375
E-mail: sanmigiz@usal.es
Thalidomide was first marketed in the 1950s for the treatment of
pregnancy-related morning sickness and later as a sedative, but was
withdrawn because of serious adverse events in pregnant women
including teratogenicity and dysmelia.1 Interest in the
drug resurfaced in the 1990s because of its antiangiogenic and
immunomodulatory effects.2 Recently thalidomide has been
used to treat multiple myeloma (MM) either alone or in combination
with other therapies. This review summarizes study results of
thalidomide treatment in patients who have not benefited from
conventional therapy. [>Read full article in
PDF]
